Therapy Areas: Vaccines
Bavarian Nordic signs new smallpox/monkeypox vaccine contracts in Canada
20 September 2022 -

Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) said on Tuesday that it has agreed a revised contract with the Public Health Agency of Canada (PHAC) to supply doses of IMVAMUNE smallpox/monkeypox vaccine at a value of approximately USD234m plus USD180m in contract options.

This extends the USD56m contract awarded in June 2022 to a total value of up to USD470m.

Bavarian Nordic has also signed a new multi-year contract with Canada's Department of National Defence (DND) at a value of USD2m, in addition to USD18m in contract options.

Under these agreements, the majority of the firm order supply will be delivered in 2023 with the option to procure additional doses annually until 2032 for a total additional value of up to USD198m.